Pfizer's Lyme Disease Vaccine Shows 70% Efficacy in Trials

Pfizer announces exciting news about a new Lyme disease vaccine. This experimental vaccine shows more than 70 percent effectiveness in reducing tick-borne infections. The study involves four doses and has been a collaboration between Pfizer and Valneva. What's interesting is that Lyme disease has been on the rise, with cases increasing in many parts of the U.S. and Europe. This vaccine could be a game changer for those living in or visiting areas where ticks are prevalent. The bottom line is that if approved, this vaccine could significantly lower the risk of Lyme disease for millions. This matters because it could lead to healthier summers for families who love the outdoors.